Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

Sponsor
Nemours Children's Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT04577417
Collaborator
(none)
50
1
9.5
5.2

Study Details

Study Description

Brief Summary

The aims of this study are to evaluate auditory sensitivity in teenagers with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART.

Condition or Disease Intervention/Treatment Phase
  • Drug: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate

Detailed Description

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Besides core ADHD symptoms (inattentiveness, hyperactivity, impulsivity), ADHD also affects the ability to perceive and process sounds. Both hypersensitivity and hyposensitivity to loud sounds are common symptoms in ADHD patients. With stimulant medication, individuals with ADHD become more tolerant of loud noise than when they were non-medicated. It remains unknown exactly how stimulant medication alters the loudness perception. The proposed study will use the acoustic reflex to objectively measure auditory sensitivity to loud sounds. The aims of this study are to evaluate auditory sensitivity in patients with ADHD using acoustic reflex thresholds (ART) and to examine the effects of ADHD stimulant medication on ART. Eligible participants will participate in two sessions (off-med and on-med conditions) conducted on the same day. ADHD patients will be asked to come to the laboratory before taking their ADHD medication. The investigators will repeat three tests before and after taking stimulant medication. The investigators will also conduct screening tests during and between the first and second sessions. The investigators will compare a difference between the two independent groups (ADHD vs. Control) and compare a within subject difference between medication conditions (on-med vs. off-med).

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Stimulant Medication Effects on Auditory Sensitivity and Acoustic Reflex in Adolescents With ADHD
Actual Study Start Date :
Sep 13, 2020
Anticipated Primary Completion Date :
Jun 30, 2021
Anticipated Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
ADHD

Adolescents, male or female, ages 13-19, diagnosed with ADHD, all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and under treatment with a stimulant medication with the same drug and dosage for at least 12 months before their study participation date

Drug: ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
Other Names:
  • Adderall
  • Focalin
  • Ritalin
  • Vyvanse
  • Concerta
  • Control

    Adolescents, male or female, ages 13-19, with normal health status and development

    Outcome Measures

    Primary Outcome Measures

    1. Acoustic reflex [through study completion, an average of 1 year]

      Acoustic reflex thresholds in each ear

    2. Loudness discomfort level [through study completion, an average of 1 year]

      Average loudness levels judged as uncomfortably loud sounds by each participant

    3. Speech perception in noise [through study completion, an average of 1 year]

      Speech perception scores in each ear measured in two separate sessions

    Secondary Outcome Measures

    1. Tympanogram [through study completion, an average of 1 year]

      Results of tympanometry (type, volume, pressure, compliance, gradient) to measure middle ear function

    2. Otoacoustic emissions [through study completion, an average of 1 year]

      Measure of inner ear function

    3. NIH Toolbox Cognition testing [through study completion, an average of 1 year]

      Measures of cognitive functions

    4. Hearing screening [through study completion, an average of 1 year]

      Pure-tone hearing test to measure hearing sensitivity

    5. Sensory profile questionnaire [through study completion, an average of 1 year]

      Sensory processing assessment

    6. Fidgeting [through study completion, an average of 1 year]

      Measure of wrist movements during the testing

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years to 19 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Inclusion criteria for all:
    • Participant must be aged 13 to 19 years

    • Males and females

    • All ethnicities

    • All socioeconomic statuses

    • Normal hearing

    • English as a primary language

    Additional inclusion criteria for ADHD group:
    • Participants must meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD), all subtypes, based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

    • Stimulant medication with the same drug and dosage for at least 1 year before their enrollment date

    Exclusion Criteria:
    • History of any major neurological disorders (e.g. seizures excluding febrile seizure under age 6 years, tumors, brain injury, cerebral palsy, tic disorders)

    • History of any other major neuropsychiatric disorders (e.g. autism spectrum disorder, mood dysregulation),

    • Presence of pressure equalization tubes in either ear

    • Documented hearing impairment 20 decibel or higher hearing loss in either ear

    • Estimated low cognitive function based on the NIH Toolbox Cognition age-corrected scores (<70)

    Additional exclusion criteria for the ADHD group

    • Treatment with any psychotropic medications other than stimulants

    • Treatment with any ADHD medication other than stimulants (e.g. alpha-agonists, norepinephrine reuptake inhibitors)

    Additional exclusion criteria for the control group

    • Treatment with any psychotropic medication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nemours Children's Health Wilmington Delaware United States 19803

    Sponsors and Collaborators

    • Nemours Children's Clinic

    Investigators

    • Principal Investigator: Kyoko Nagao, PhD, Nemours

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nemours Children's Clinic
    ClinicalTrials.gov Identifier:
    NCT04577417
    Other Study ID Numbers:
    • 1600804
    First Posted:
    Oct 6, 2020
    Last Update Posted:
    Oct 6, 2020
    Last Verified:
    Sep 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Nemours Children's Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2020